AAP
MLTX icon

Arax Advisory Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Arax Advisory Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93 Buy
+5
New +$83 ﹤0.01% 3621
2025
Q4 		– Sell
-82
Closed -$588 – 4362
2025
Q3 		$588 Buy
+82
New +$4.27K ﹤0.01% 3348

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arax Advisory Partners's MLTX Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 5 shares worth $93. The stake represents ﹤0.01% of the portfolio and ranks #3621 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in MLTX as recently as Q3 2025.

Arax Advisory Partners first reported a position in MLTX in Q3 2025 and has held it in 2 quarters since. The position peaked at $588 in Q3 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Arax Advisory Partners held 5 shares of MoonLake Immunotherapeutics worth $93 as of Q1 2026.
  • MoonLake Immunotherapeutics was a new Arax Advisory Partners position in Q1 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3621 holding.
  • Arax Advisory Partners first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's MoonLake Immunotherapeutics position peaked at $588 in Q3 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.